Material
Synthetic heptapeptide analogue

Prepared for laboratory investigation of neurotrophic signaling and cognitive research models.
* Vial labels may use shortened names to keep the label legible. The full material and composition are stated in this profile.
Synthetic heptapeptide analogue
Single peptide material.
Neurotrophic peptide research.
Interest in Semax centers on BDNF-related signaling, neuroplasticity, cognitive models, and the biology of recovery after neurological stress.
BDNF, TrkB, and neurotrophic signaling
Neuroprotection, cognition, and stroke-recovery models
A source-led view of the findings reported to date, the maturity of the evidence, and the limits that matter when interpreting it.
Animal studies report changes in BDNF/TrkB signaling and learning-related measures. Small, regionally concentrated human studies have reported changes in BDNF and functional recovery after stroke, but broad independent confirmation is limited.
The evidence mixes mechanistic animal work with limited human studies. It is not sufficient to generalize a clinical effect across neurological or cognitive conditions.
This summary describes published research on the named material or its components. It does not establish safety, efficacy, equivalence, or suitability of this Veyvanta research product for human use.
Convert a declared vial amount and diluent volume into nominal concentration, liquid volume, and the equivalent position on a U-100 scale.
Enter a positive diluent volume and target amount to calculate.
This tool performs unit conversion only. It does not recommend an amount, frequency, route, diluent, handling method, or human use. Results assume ideal mixing and a U-100 scale of 100 units per mL; validated laboratory procedures and material-specific compatibility take priority.
This is the evergreen product profile. Enter the code from a physical vial to display its specific record.
Verify this vialThis QR code opens the current product profile with its associated vial record.